CYCC Cyclacel, Inc. Company Short-Term Debt

Public company logo of Cyclacel, Inc. (CYCC)

The price action of Cyclacel Pharmaceuticals (CYCC) on the GURU.Markets platform captures the 0.00 metric, illustrating the company's activities in the field of oncology. The business relies on the humanitarian status of medicine, which provides it with diplomatic immunity and stability. However, risks of reagent supply disruptions and complexities regarding software intellectual property protection across different countries remain relevant. Patient safety depends directly on the quality of international component transportation.

CYCC (Cyclacel) Company Short-Term Debts history from 07/04/2022 to 09/12/2025

Analytical breakdowns for Cyclacel, Inc. (CYCC)

- stock price and consensus target price:
Stock Price Cyclacel|CYCC - Average Forecast Price
- market capitalization data:
Market Value Cyclacel Pharmaceuticals|CYCC - Value Adjusted for Debt and Cash
- shareholders' equity book value data:
Book Value per Share Cyclacel|CYCC - Book Capitalization|Market Value to Book Value Ratio cyclacel.com|CYCC - Aggregate Company Assets
- debt obligations and liquidity statistics:
Total Debt to Equity Ratio Cyclacel Pharmaceuticals|CYCC - Long-Term Debt to Capital Coefficient|Short-Term Debt to Equity Cyclacel Pharmaceuticals|CYCC - Company Cumulative Debt|Debt to Book Capitalization Ratio Cyclacel Pharmaceuticals|CYCC - Company Long-Term Indebtedness|Company Short-Term Debts Cyclacel|Quick Liquidity cyclacel.com
- net income and valuation multiples indicators:
CYCC - Company Net Income
Basic company analysis:CYCC - Cyclacel
Flagship merchandise of Cyclacel Pharmaceuticals

When constructing a long-term portfolio, liquidity screening allows for the assessment of default risk by analyzing liabilities with maturities of up to one year. The current value of 0.00 reflects the total volume of short-term loans, which, combined with the transparent management of R&D expenses by the Cyclacel Pharmaceuticals (CYCC) team, helps investors track the effectiveness of mitigating cash flow gaps regarding the company's short-term debt.

Direct competitors

Incyte - Company Short-Term Debts|Short-Term Debt Hutchison MediPharma|Nuvation Pharma (NUVB) - Company Short-Term Debt|Day One Biopharmaceuticals Inc - Company Short-Term Loans and Borrowings|MNPR (Monopar Therapeutics) - Company Short-Term Debts|Company Short-Term Debts inhibrx.com|Company Short-Term Debt I-Mab (IMAB)|Company Short-Term Debt FENC (Fennec Pharma)|Heron Therapeutics, Inc. - Company Current Liabilities|Company Short-Term Loans and Borrowings NVCT|CHRS - Company Short-Term Debt|Short-Term Debt corbuspharma.com|cardiffoncology.com (CRDF) - Company Short-Term Debt|Company Short-Term Indebtedness BYSI|BCAB (BioAtla Inc) - Company Short-Term Debts|Company Current Liabilities Lixte Biotechnology, Inc. (LIXT)|Company Short-Term Debt Citius Pharmaceuticals (CTXR)|CLRB - Short-Term Debt|Company Short-Term Debt BioLineRx BLRX|Can-Fite BioPharma Ltd - Company Short-Term Debt|APRE - Company Short-Term Debt|Short-Term Debt Kazia Therapeutics|SLXN: Company Short-Term Debts|Short-Term Indebtedness NuCana NCNA|Company Current Liabilities CMRX|Short-Term Debt G1 Pharma GTHX|Company Current Liabilities KRON (Kronos Bio Corp)|KTRA (Kintara Pharma) - Company Short-Term Loans and Borrowings|Oncternal Therapeutics - Company Current Liabilities|Amount of Current Liabilities PRTG (portagebiotech.com)